Lobbying Update: $1,170,000 of TENET HEALTHCARE CORPORATION lobbying was just disclosed

$1,170,000 of TENET HEALTHCARE CORPORATION lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"Hospital and physician payments under Medicare and Medicaid, general. Medicare/ Medicaid Reform- (Bundling of Medicare acute and post-acute hospital payments, payments for readmissions, value-based purchasing, physician self-referral)- Implementation of the Health Care and Education Reconciliation Act of 2012 (Pub. Law 111-143). Medicare site neutral payments Federal exchange subsidies under The Affordable Care Act Medicare and Medicaid Disproportionate Share Hospital funding Accountable Care Organization (ACO) programs CHGME ACA Stabilization Price Transparency Save the DA Act Telehealth 340B Medicare payment policy: IPPS/OPPS Graduate Medical Education (GME) Outpatient Surgery Quality and Access Act Medicaid Fiscal Accountability Regulation (MFAR) ACA premium tax credits Hospital and physician payments under Medicare and Medicaid, general. Medicare/ Medicaid Reform- (Bundling of Medicare acute and post-acute hospital payments, payments for readmissions, value-based purchasing, physician self-referral)- Implementation of the Health Care and Education Reconciliation Act of 2012 (Pub. Law 111-143). Medicare site neutral payments Federal exchange subsidies under The Affordable Care Act Medicare and Medicaid Disproportionate Share Hospital funding Accountable Care Organization (ACO) programs CHGME ACA Stabilization Price Transparency Telehealth 340B Medicare payment policy: IPPS/OPPS Graduate Medical Education (GME) Outpatient Surgery Quality and Access Act Medicaid Fiscal Accountability Regulation (MFAR) ACA premium tax credits House and Senate Budgets as pertain to Medicare and Medicaid. Consumer Financial Protection Bureau Rulemaking Tax Reform FTC non-compete rulemaking"

You can find more data on corporate lobbying on Quiver Quantitative.

THC Congressional Stock Trading

Members of Congress have traded $THC stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $THC stock by members of Congress over the last 6 months:

REPRESENTATIVE JONATHAN L. JACKSON purchased up to $15,000 on 09/03.
REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 06/11 and 1 sale worth up to $15,000 on 08/04.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

THC Insider Trading Activity

THC insiders have traded $THC stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.

Here’s a breakdown of recent trading of $THC stock by insiders over the last 6 months:

SAUMYA SUTARIA (CEO) has made 0 purchases and 2 sales selling 78,762 shares for an estimated $15,026,139.
JAMES L BIERMAN has made 0 purchases and 4 sales selling 20,000 shares for an estimated $3,249,258.
PAOLA M ARBOUR (EVP, Chief Information Officer) has made 0 purchases and 2 sales selling 14,199 shares for an estimated $2,373,726.
THOMAS W ARNST (EVP, Chief Admin. Officer & GC) sold 9,786 shares for an estimated $1,624,476
LISA Y FOO (EVP, Chief Operating Officer) sold 8,000 shares for an estimated $1,436,240
J ROBERT KERREY has made 0 purchases and 3 sales selling 6,223 shares for an estimated $944,234.
CHRISTOPHER S. LYNCH has made 0 purchases and 2 sales selling 3,960 shares for an estimated $698,560.
RICHARD W FISHER has made 0 purchases and 2 sales selling 3,913 shares for an estimated $654,682.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

THC Hedge Fund Activity

We have seen 306 institutional investors add shares of THC stock to their portfolio, and 299 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

INVESCO LTD. removed 1,364,955 shares (-32.7%) from their portfolio in Q2 2025, for an estimated $240,232,080
BOSTON PARTNERS added 1,095,630 shares (+94.2%) to their portfolio in Q2 2025, for an estimated $192,830,880
NUVEEN, LLC removed 932,271 shares (-57.4%) from their portfolio in Q2 2025, for an estimated $164,079,696
ALLIANCEBERNSTEIN L.P. added 624,125 shares (+375.7%) to their portfolio in Q2 2025, for an estimated $109,846,000
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 607,637 shares (-51.1%) from their portfolio in Q2 2025, for an estimated $106,944,112
HOLOCENE ADVISORS, LP added 584,404 shares (+inf%) to their portfolio in Q2 2025, for an estimated $102,855,104
BLACKROCK, INC. removed 554,264 shares (-5.8%) from their portfolio in Q2 2025, for an estimated $97,550,464

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

THC Analyst Ratings

Wall Street analysts have issued reports on $THC in the last several months. We have seen 13 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Mizuho issued a "Outperform" rating on 10/17/2025
Goldman Sachs issued a "Buy" rating on 10/14/2025
Keybanc issued a "Overweight" rating on 10/08/2025
Barclays issued a "Overweight" rating on 09/18/2025
B of A Securities issued a "Buy" rating on 09/10/2025
Cantor Fitzgerald issued a "Overweight" rating on 08/26/2025
Wells Fargo issued a "Overweight" rating on 08/14/2025

To track analyst ratings and price targets for THC, check out Quiver Quantitative's $THC forecast page.

THC Price Targets

Multiple analysts have issued price targets for $THC recently. We have seen 16 analysts offer price targets for $THC in the last 6 months, with a median target of $207.5.

Here are some recent targets:

Ann Hynes from Mizuho set a target price of $225.0 on 10/17/2025
Scott Fidel from Goldman Sachs set a target price of $224.0 on 10/14/2025
Scott Schoenhaus from Keybanc set a target price of $225.0 on 10/08/2025
Sarah James from Cantor Fitzgerald set a target price of $190.0 on 10/07/2025
Stephen Baxter from Wells Fargo set a target price of $238.0 on 10/07/2025
Andrew Mok from Barclays set a target price of $229.0 on 09/18/2025
Kevin Fischbeck from B of A Securities set a target price of $225.0 on 09/10/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.